未登录 Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC 整合机器学习预测与因果推断分析，以揭示EGFR突变、晚期非小细胞肺癌进展的决定因素 Bozcuk, H.; Sert, L.; Kaplan, M. A.; Tatli, A. M.; Karaca, M.; Kilictas, B.; Artac, M.; Sendur, M. A. N.; Bilgin, B.; Balli, S.; Demirkazik, A.; Kilickap, S.; Taban, H.; Guzel, H. G.; Kocer, M.; Koylu, B.; Biricik, F. S.; Karakaya, G.; Coskun, H. S.; Alemdar, M. S. 分享 收藏
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 一线nivolumab联合ipilimumab与化疗在不可切除的恶性胸膜间皮瘤患者中的比较: CheckMate 743的3年结果 Peters, S.; Scherpereel, A.; Cornelissen, R.; Oulkhouir, Y.; Greillier, L.; Kaplan, M. A.; Talbot, T.; Monnet, I; Hiret, S.; Baas, P.; Nowak, A. K.; Fujimoto, N.; Tsao, A. S.; Mansfield, A. S.; Popat, S.; Zhang, X.; Hu, N.; Balli, D.; Spires, T.; Zalcman, G. 分享 收藏
First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743 Peters, S.; Scherpereel, A.; Cornelissen, R.; Oulkhouir, Y.; Greillier, L.; Kaplan, M. A.; Talbot, T.; Monnet, I.; Hiret, S.; Baas, P.; Nowak, A. K.; Fujimoto, N.; Tsao, A. S.; Mansfield, A. S.; Popat, S.; Zhang, X.; Hu, N.; Balli, D.; Sanzari, J.; Zalcman, G. 分享 收藏
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases Oruc, Zeynep; Kaplan, M. Ali; Karaagac, Mustafa; Ozyurt, Neslihan; Tatli, Ali Murat; Kaya, Ali Osman; Menekse, Serkan; Kut, Engin; Koca, Sinan; Sever, Ozlem Nuray; Yasin, Irem; Ebinc, Senar; Zeynelgil, Esra; Sakin, Abdullah; Turhal, Nazim Serdar; Isikdogan, Abdurrahman 分享 收藏
Multicenter real life experience of biological agents in patients with metastatic colorectal cancer Demirci, U.; Erturk, I.; Arslan, C.; Bilici, A.; Cevik, D.; Cicin, I.; Dane, F.; Dolek, B.; Kaplan, M.; Karadurmus, N.; Kose, F.; Sendur, M.; Urun, Y.; Kilickap, S. 分享 收藏
EFFICACY OF ADJUVANT 9-WEEKS TRASTUZUMAB IN NODE-NEGATIVE T1A/B HER2-POSITIVE BREAST CANCER 9周曲妥珠单抗辅助治疗淋巴结阴性T1A/B HER2-POSITIVE乳腺癌的疗效 Sendur, M. A.; Aksoy, S.; Uncu, D.; Demir, H.; Yuksel, S.; Ekinci, A. S.; Kaplan, A.; Ustaalioglu, B. B.; Tufan, G.; Inanc, M.; Ozdemir, N.; Artac, M.; Tastekin, D.; Kacan, T.; Oguz, A.; Arpaci, E.; Yazilitas, D.; Gumus, M.; Zengin, N.; Altundag, M. K. 分享 收藏
分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
